Richard McKernan
Chairman of the Board

Mr. Richard McKernan is the Chairman of Medicinal Genomics Company.  Historically, he was President of Packard Instrument Company from 1986 to 2000  and a Senior Vice President and member of the Board of Packard BioScience Company.  He was responsible for the development and execution of the strategic plan and the performance of Packard Instrument Company, its domestic and international sales subsidiaries.  Mr. McKernan was the lead presenter in the initial public stock  offering of Packard Bioscience Company  and participated in the negotiations for the acquisition of Packard by PerkinElmer Corporation.  He has had 40 years of management experience with 20 years in the Life Sciences Industry.  Mr. McKernan’s management experience includes engineering, operations, domestic and international sales and service, marketing, and strategic planning. He has managed the turnarounds of five companies, led the acquisition and divestiture of  Packard BioScience.  In the past, he served as the Chairman of Agencourt Bioscience Corporation,  Agencourt Personal Genomics and Courtagen Life Sciences Inc.   During his career, Mr. McKernan was a key participant on management teams that created over $1 billion in shareholder wealth.   He received a Bachelor’s degree in Electrical Engineering from Pennsylvania State University and a Master’s degree in Electrical Engineering from the University of Connecticut.

Phillip Chapman
Board Member

Philip is a Founder and Managing Member of JPL Advisors LLC and JPL Management Services LLC. His responsibilities include portfolio management and client development. Philip has been President of Adler & Co, a family office for over twenty five years managing portfolios of direct investments in both public and private companies, hedge funds, venture capital, and private equity funds. Philip has sat on the boards of multiple companies. He was also a Managing Member of Alpha Beta Capital Management LLC, a fund of hedge funds. Philip was previously a management consultant with Booz Allen & Hamilton in London. He received his B.S. from Columbia University and his MBA from Columbia Business School.

Mark H. Deblois
Board Member

Mark H. DeBlois is a co-founder and Managing Partner of Bunker Hill Capital. Mark has over 28 years of experience working as a controlling investor with middle market companies. He is active working with portfolio companies in the role of lead investor with extensive board-level and strategic planning experience. Mark currently sits on the boards of directors of Bunker Hill Capital portfolio companies ASPEQ Heating Group, Dyno Holdings, Hubbardton Forge, Nexus Brands Group, Rizing, Specialty Brands Holdings and Taos Mountain and sat on the boards of directors of Specialty Coating Systems and SunBrite Holding Corporation prior to their sale. Prior to founding Bunker Hill Capital, Mark was a Managing Director at BancBoston Capital where he was involved in a similar capacity investing in over 20 companies. Prior to joining BancBoston Capital, Mark worked for Bank of Boston primarily providing financing to middle market companies. Mark holds a B.A. from Boston College.

Charles Farkas
Board Member

Charles Farkas is an advisory partner of Bain & Company.  He joined the firm in 1979 and was elected to the partnership in 1985.  Mr. Farkas advises chief executives and senior managers on issues critical to long-term success.  He was the founder of Bain and Company’s Hospital Consulting Practice in 1985, he served as Chairman, Bain Canada from 1992-1994, the Global Leader of Bain & Company’s Financial Services Practice from 1995-1999, and the North American Head of Bain’s Healthcare Practice from 2004-2008

His primary focus over the past 37 years has been healthcare.  He has worked globally with 4 of the 5 leading medical technology companies, 8 of the 10 largest pharmaceutical companies, many of the leading academic medical centers, and a variety of leading healthcare providers and service companies.  He also advises a number of healthcare start-up companies and private equity investors in healthcare.  Mr. Farkas has extensive experience with healthcare M&A, growth strategies, productivity improvement, and merger integration.

With over 37 years consulting experience, Mr. Farkas is highly sought out by clients for his experience with issues of growth, strategy, leadership and change.  He is the author of the best-selling book Maximum Leadership (1996) and numerous articles in the Harvard Business Review, Fortune, In Vivo, and other publications.  In 2008 Consulting Magazine named Mr. Farkas on the Top 25 Consultants in America.

Mr. Farkas earned an MBA from Harvard Business School.  He is a graduate of Princeton University where he received a Bachelor of Arts in History with honors.  From 1976-1978, Mr. Farkas was ITT International Fellow in Manila, Philippines.

Brendan McKernan
Board Member & CEO

Brendan has spent his career utilizing world class operating principles in the life science and clinical diagnostic industries. The Medicinal Genomics (MGC) team has a finite attention to detail to ensure that MGC can and will produce the finest quality products in the world. This approach has been part of MGCs culture and a strong passion of Brendan’s his entire career. Brendan has had the opportunity to work with incredibly bright scientists, entrepreneurs and business professionals while building Agencourt Bioscience, Agencourt Personal Genomics, Courtagen Life Sciences and Medicinal Genomics.

Brendan holds a BS in Management Science from Muhlenberg College and an MBA from Rensselaer’s Lally School of Management and Technology. While at Rensselaer, Brendan received the Delmar W. Karger Award in Management for outstanding academic and leadership achievements. In 2006 Brendan was named the William F. Glaser ’53 Rensselaer Entrepreneur of the Year. Brendan is also a board member of the Avon Old Farms School where he serves as Co-Vice Chairman and Treasurer. In addition, Brendan is a member of Boston Harbor Angels and an advisor to Rensselaer’s Lally School of Management and Technology. When not not pushing for lean manufacturing concepts, Brendan enjoys boating and martial arts.

Richard Upton
Board Member

Richard Upton is a General Partner of Harbor Light Capital Partners, an early-stage venture capital firm.  Previously, he was founder and President of Upton Advisors, a boutique investment bank serving middle market and emerging healthcare companies. Mr. Upton has been advising early-stage companies since 1992 both as an investment banker for Salomon Brothers and later as an independent advisor. Mr. Upton has completed engagements representing aggregate transaction values in excess of $5 billion. Mr. Upton currently serves on the Boards of Alcyone Lifesciences, Carmell Therapeutics and Medicinal Genomics Corp., and previously served on the Boards of Home Diagnostics, Inc. (NASDAQ: HDIX – acquired by Nipro Corporation), Courtagen Life Sciences and Castlewood Surgical. Mr. Upton is a member of the Investment Committee of the New Hampshire Charitable Foundation, and is former Chairman of The Pine Hill Waldorf School. Mr. Upton is a founding member of Northeast Angels, an early-stage angel investing group. He has also been a youth hockey coach since 2001. Mr. Upton received his MBA degree from The Darden School at the University of Virginia and a dual BA degree in Economics and English from Amherst College.

Tracy Marshbanks
Board Observer

Tracy is a managing director at First Analysis coordinating investment and research in medical and pharma technology along with clean-tech and chemicals. He specializes in businesses where chemical and medical technologies are a key differentiating element. Prior to joining First Analysis in 1999, he held a number of positions with Amoco Corp. ranging from R&D to Marketing & Capital Planning. He earned an MBA from the University of Chicago, a doctorate in chemical engineering from Purdue University, and a bachelor’s degree in chemical engineering from Colorado State University.  He has served as a director for a number of companies including one public company.